THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

NCT ID: NCT02732704

Last Updated: 2022-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-20

Study Completion Date

2027-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic regurgitation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcatheter Aortic Valve Replacement (TAVR)

TAVR with JenaValve Pericardial Valve and Delivery System

Group Type EXPERIMENTAL

JenaValve Pericardial TAVR System

Intervention Type DEVICE

TAVR with JenaValve Pericardial Valve and Delivery System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JenaValve Pericardial TAVR System

TAVR with JenaValve Pericardial Valve and Delivery System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with severe aortic regurgitation (AR).
* Patient at high risk for open surgical valve replacement
* Patient symptomatic according to NYHA functional class II or higher
* The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.

Exclusion Criteria

* Congenital uni or bicuspid aortic valve morphology
* Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
* Endocarditis or other active infection
* Need for urgent or emergent TAVR procedure for any reason
* Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device
* Severe mitral regurgitation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

JenaValve Technology, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin B. Leon, MD

Role: STUDY_CHAIR

New York-Presbyterian/ Columbia University Medical Center

Torsten P. Vahl, MD

Role: PRINCIPAL_INVESTIGATOR

New York-Presbyterian/ Columbia University Medical Center

Vinod H. Thourani, MD

Role: PRINCIPAL_INVESTIGATOR

Piedmont Healthcare

Stephan Baldus, MD

Role: PRINCIPAL_INVESTIGATOR

Herzzentrum der Universität zu Köln

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

California Pacific Medical Center Research Institute

San Francisco, California, United States

Site Status

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Piedmont Healthcare

Atlanta, Georgia, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

New York-Presbyterian/ Columbia University Medical Center

New York, New York, United States

Site Status

Baylor Scott & White Research Institute

Dallas, Texas, United States

Site Status

University of Washington

Seattle, Washington, United States

Site Status

Kerckhoff-Klinik GmbH Bad Nauheim

Bad Nauheim, , Germany

Site Status

Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum Bad Oeynhausen

Bad Oeynhausen, , Germany

Site Status

Deutsches Herzzentrum Berlin

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Herzzentrum der Universität zu Köln

Cologne, , Germany

Site Status

Universitätsklinikum Frankfurt

Frankfurt, , Germany

Site Status

Universitäres Herzzentrum Hamburg

Hamburg, , Germany

Site Status

Leiden University Medical Center

Leiden, , Netherlands

Site Status

St. Antonius Hospital

Nieuwegein, , Netherlands

Site Status

Erasmus University Medical Center

Rotterdam, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Hamid N, Ranard LS, Khalique OK, Hahn RT, Nazif TM, George I, Ng V, Leon MB, Kodali SK, Vahl TP. Commissural Alignment After Transfemoral Transcatheter Aortic Valve Replacement With the JenaValve Trilogy System. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2079-2081. doi: 10.1016/j.jcin.2021.07.025. No abstract available.

Reference Type DERIVED
PMID: 34556282 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P02C320_JV06EFS_CIP

Identifier Type: OTHER

Identifier Source: secondary_id

CA-0002 EU

Identifier Type: OTHER

Identifier Source: secondary_id

CA-0002 Germany

Identifier Type: OTHER

Identifier Source: secondary_id

CA-0011

Identifier Type: OTHER

Identifier Source: secondary_id

CP-0004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ALLEVIATE-HFrEF Study
NCT05133089 COMPLETED PHASE1
AVJ-514 Japan Trial
NCT02520310 COMPLETED NA
Venus-Vitae Pivotal Study Smart-Align Study
NCT05991271 NOT_YET_RECRUITING NA